Myriad Presents New Data at ASCO Validating the Ability of riskScore® to Provide Personalized Breast Cancer Risk Information to Patients

SALT LAKE CITY, May 29, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, today announced the presentation of two new studies at the 2020 American Society of Clinical Oncology (ASCO) annual meeting demonstrating the ability of Myriada??s riskScore test to provide personalized breast cancer risk information that allows patients and physicians to make better informed clinical treatment decisions.
a??We are excited to further demonstrate Myriada??s commitment to providing the best possible risk assessment tools to patients through innovation,a?? said Nicole Lambert, president of Myriad Oncology, Myriad Womena??s Health and Myriad International. a??The validation data we are presenting at ASCO this year will support a broader launch of riskScore to even more women in the coming year with more personalized information and the unique ability to modify carrier risk through a clinically validated tool.a??
Summaries of the studies are below. Follow Myriad on Twitter via @myriadgenetics and keep up to date with ASCO meeting news and updates by using the #ASCO20 hashtag.riskScore Presentations at 2020 ASCO:Title:A Comprehensive breast cancer (BC) risk assessment for CHEK2 carriers incorporating a polygenic risk score (PRS) and the Tyrer-Cuzick (TC) model
Presenter:A Mark E. Robson, MD, Memorial Sloan Kettering Cancer Center
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«    Июль 2020    »